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Dietary restriction (DR) is a well-known intervention to 
slow down the aging of cells and organisms. Although 
the molecular mechanisms by which DR prolongs 
lifespan are poorly understood, the Target of 
Rapamycin Complex 1 (TORC1) signaling pathway that 
controls protein translation, autophagy and 
mitochondrial function, among other growth-related 
processes, is considered a main player mediating DR 
effects in diverse model organisms. Inhibition of 
TORC1 by nutrient limitation or by drugs prolongs 
lifespan [1], and reduced protein translation has been 
linked to increased lifespan in several organisms [2]. 
 
Fission yeast is emerging as a complementary model 
system to budding yeast for cellular ageing. Caffeine 
and rapamycin treatment trigger a range of phenotypes 
relating to TORC1 inhibition in fission yeast: gene 
expression reprogramming, inhibition of global protein 
translation, reduced cell growth, and extension of 
chronological lifespan [3]. Rapamycin and caffeine 
differentially affect these conserved, TORC1-dependent 
processes. For example, caffeine inhibits global protein 
translation much more than does rapamycin. 
Combination of the two drugs often augments the 
phenotypes observed. Drug synergies utilised to either 
effectively block a sole pathway, or a combination of 
pathways, are promising for aging studies and the 
treatment of age-related diseases. For example, 
combination of low doses of rapamycin and myriocin 
enhances autophagy, mitochondrial function, AMP 
kinase pathway activity and genomic stability in 
budding yeast [4].  
 
How are TORC1 activity and global protein translation 
associated with the aging process? Recent results from 
mammalian cell lines indicate that constitutively active 
TORC1 signaling augments overall protein synthesis by 
increasing the speed of ribosomal elongation along 
transcripts [5]. Notably, this increased translational 
elongation leads to decreased translational fidelity, 
possibly by promoting misincorporation of amino acids 
and compromising the co-translational folding of 
polypeptides. Rapamycin treatment restores the high 
quality of newly synthesized proteins by slowing the 
rate of ribosomal elongation, allowing enhanced  quality  
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control [5]. In fission yeast, rapamycin prolongs the 
chronological lifespan of non-dividing, quiescent cells 
only when administered to cells that are still 
proliferating, while rapamycin treatment of cells that 
have entered quiescence does not affect their lifespan 
[3]. This intriguing phenomenon highlights an 
information flow from cellular growth, when TORC1 is 
active, to cellular quiescence, when it is not. It is 
plausible that this phenomenon is caused rapamycin 
increasing protein quality at the expense of protein 
quantity [5]. A lowered translational activity during cell 
growth could reduce waste and rogue proteins that 
would otherwise compromise the longevity of quiescent 
cells. Similarly, fission yeast cells that are grown slowly 
in low glucose medium show increased lifespan during 
quiescence [6], which also could be explained by the 
increased translation fidelity through decreased TORC1 
activity. Both in fission yeast and mammalian cell lines, 
rapamycin mediates its inhibitory effect on protein 
translation via ribosomal S6 kinases (S6K) [3,5], and 
S6K is key in restoring translational fidelity upon 
rapamycin treatment [5]. 
 
Does dietary restriction have the same effect on protein 
quality at the organismal level, and how much does this 
effect contribute to longevity? Moreover, as TORC1 
signaling also controls gene transcription, does over-
activation of this pathway cause similar fidelity issues 
for transcripts as for proteins? The hyperfunction theory 
of aging postulates that the proximal cause of aging is 
not the accumulation of random molecular damage but 
overactive cellular functions [7]. While increased 
random damage of existing molecules might not 
significantly contribute to aging, is it possible that 
TORC1-driven hyperfunction leads directly to the 
increased synthesis of rogue proteins that cause 
pathologies and compromise longevity? If cellular 
hyperfunction underlies the aging process, what would 
be the contribution of any associated defects in protein 
homeostasis in the whole process? A grand challenge in 
aging research is to define all the factors that affect 
longevity and uncover any universal causes of cellular 
and organismal aging. The nutrient-sensing TORC1 
signaling pathway seems to be a key contributor: its 
inhibition by drugs or dietary restriction reduces protein 
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translation, apparently allowing for better quality 
control. Accumulation of faulty and mis-folded proteins 
might thus be reduced, which otherwise would directly 
contribute to age-related cellular pathologies.   
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